Deep Medicine Acquisition (Deep Medicine Acquisition) Cash, Cash Equivalents, Marketable Securities : $0.36 Mil (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Deep Medicine Acquisition Cash, Cash Equivalents, Marketable Securities?

Deep Medicine Acquisition's quarterly cash, cash equivalents, marketable securities declined from Mar. 2023 ($0.60 Mil) to Jun. 2023 ($0.54 Mil) but then stayed the same from Jun. 2023 ($0.54 Mil) to Sep. 2023 ($0.36 Mil).

Deep Medicine Acquisition's annual cash, cash equivalents, marketable securities increased from Mar. 2021 ($0.50 Mil) to Mar. 2022 ($0.88 Mil) but then declined from Mar. 2022 ($0.88 Mil) to Mar. 2023 ($0.60 Mil).

Deep Medicine Acquisition Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Deep Medicine Acquisition's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Deep Medicine Acquisition Cash, Cash Equivalents, Marketable Securities Chart

Deep Medicine Acquisition Annual Data

Trend

Mar21

Mar22

Mar23

Cash, Cash Equivalents, Marketable Securities

0.50

0.88

0.60

Deep Medicine Acquisition Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial							0.52	0.96	0.60	0.54	0.36

Deep Medicine Acquisition Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Deep Medicine Acquisition (NAS:DMAQ) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Deep Medicine Acquisition Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Deep Medicine Acquisition's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Deep Medicine Acquisition (Deep Medicine Acquisition) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Deep Medicine Acquisition Corp (NAS:DMAQ) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

595 Madison Avenue, 12th Floor, New York, NY, USA, 10017

Website

Deep Medicine Acquisition Corp is a blank check company.

Executives

John Chiang	director	3538 TORRANCE BLVD., UNIT 177, TORRANCE CA 90503
Bryant Fong	director	2170 VALLEJO STREET #101, SAN FRANCISCO CA 94123
Humphrey P Polanen	director, officer: Chief Executive Officer	C/O HERITAGE COMMERCE CORP, 150 ALMADEN BLVD, SAN JOSE CA 95113
Weixuan Luo	officer: Chief Financial Officer	40 WALL STREET, 29TH FLOOR, NEW YORK NY 10005
Marc Hamer	director	7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Bright Vision Sponsor Llc	10 percent owner	7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Ronald M. Razmi	director	7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Hongliang Ren	director	7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Wanlei Miao	director	595 MADISON AVENUE, 12TH FLOOR, NEW YORK NY 10017
Tina Spires	director	595 MADISON AVENUE, 12TH FLOOR, NEW YORK NY 10017